In the wake of the increase in Current Liabilities in the third quarter 2025, Quick Ratio fell to 0 a new company low.

Within Biotechnology & Pharmaceuticals industry 132 other companies have achieved higher Quick Ratio than Zivo Bioscience Inc in third quarter 2025. While Quick Ratio total ranking in the third quarter 2025 has deteriorated compared to the prior quarter from 3469 to 3698.

Explain Quick Ratio?
How much Cash & cash equivalents ZIVO�s has?
What are ZIVO�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ZIVO Quick Ratio	(Sep 30 2025) Q3	(Jun 30 2025) Q2	(Mar 31 2025) Q1	(Dec 31 2024) Q4	(Sep 30 2024) Q3
Y / Y Current Liabilities Change	40.16 %	3.08 %	-15.32 %	-35.49 %	-18.76 %
Y / Y Cash & cash equivalent Change	-79.1 %	-76.04 %	-76.04 %	-75.98 %	14.6 %
Quick Ratio MRQ	0	0	0	0	0.01
ZIVO's Total Ranking	# 3698	# 3469	# 3217	# 3399	#
Seq. Current Liabilities Change	22.12 %	13.28 %	46.66 %	-30.91 %	-10.19 %
Seq. Cash & cash equivalent Change	0 %	0 %	-0.26 %	-79.04 %	14.6 %

Quick Ratio third quarter 2025 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 133
Healthcare Sector	# 838
Overall Market	# 3698

Quick Ratio Statistics
High	Average	Low
3.38	0.35	0
(Sep 30 2021)		(Mar 31 2019)

Financial Statements
Zivo Bioscience Inc 's Current Liabilities	$ 4 Millions	Visit ZIVO's Balance sheet
Zivo Bioscience Inc 's Cash & cash equivalent	$ 0 Millions	Visit ZIVO's Balance sheet
Source of ZIVO's Sales		Visit ZIVO's Sales by Geography

Cumulative Zivo Bioscience Inc 's Quick Ratio

ZIVO's Quick Ratio for the trailling 12 Months

ZIVO Quick Ratio	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months	(Mar 31 2025) 12 Months	(Dec 31 2024) 12 Months	(Sep 30 2024) 12 Months
Y / Y Current Liabilities TTM Growth	-2.91 %	-16.48 %	-23.24 %	-17.67 %	-4.24 %
Y / Y Cash & cash equivalent TTM Growth	-76.87 %	-53.37 %	-34.36 %	-15.34 %	-93.1 %
Quick Ratio TTM	0	0.01	0.01	0.01	0.01
Total Ranking TTM	# 4262	# 2810	# 2593	# 3518	#
Seq. Current Liabilities TTM Growth	10.43 %	0.9 %	-4.58 %	-8.68 %	-5.01 %
Seq. Cash & cash equivalent TTM Growth	-48.59 %	-28.96 %	-22.46 %	-18.33 %	3.65 %

Quick ratio ranking by company, industry and sector >> Back to ZIVO Financial Strength Comparisons >> Go to Compare ZIVO Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q3 2025 to $3.61 millions, cumulative Quick Ratio decreased to 0 below the Zivo Bioscience Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 161 other companies have achieved higher Quick Ratio than Zivo Bioscience Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2025 from 2810 to 4262.

Explain Quick Ratio?
How much Cash & cash equivalents ZIVO�s has?
What are ZIVO�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 162
Healthcare Sector	# 1019
Within the Market	# 4262

trailing twelve months Quick Ratio Statistics
High	Average	Low
2.92	0.33	0
(Mar 31 2022)		(Sep 30 2015)

Companies with similar Quick Ratio in the quarter ending Sep 30 2025, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Sep 30 2025 MRQ Cash & cash equivalent	Sep 30 2025 MRQ Current Liabilities
Mosaic Immunoengineering Inc	0.01	$ 0.032 Millions	$ 5.915 Millions
Black Hawk Acquisition Corporation	0.01	$ 0.015 Millions	$ 2.961 Millions
Scilex Holding Company	0.00	$ 0.878 Millions	$ 358.948 Millions
Zivo Bioscience Inc	0.00	$ 0.008 Millions	$ 3.614 Millions
Gilead Sciences Inc	0.00	$ 19.000 Millions	$ 12,298.000 Millions
Cel sci Corporation	0.00	$ 0.007 Millions	$ 5.131 Millions
Brainstorm Cell Therapeutics inc	0.00	$ 0.005 Millions	$ 9.023 Millions

Date modified: 2026-09-08T15:11:35+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.